Home measurement of blood pressure (BP) can improve compliance. The aim of this study was to evaluate if the efficacy of losartan in hypertension could be enhanced by providing patients with a device for home BP measurement. In this open, randomised, prospective, multi-centre study in 244 Swiss practices, patients with mild-to-moderate hypertension were randomised to a group receiving a home BP measuring device (OMRON) (group 2), or to a group where this device was not provided (group 1). After 8 weeks of treatment with losartan, the responder rates between subjects performing home measurement of BP were compared with those without self-measurement, whereby exclusively sphygmomanometric office BP values were considered. A total of 622 subjects completed the study. Treatment with losartan significantly reduced diastolic (DBP) and systolic BP (SBP) (P Ͻ 0.0001). Overall, the group with
Introduction

General aspects
Hypertension is one of the most common pathological conditions in daily medical practice. High blood pressure (BP), obesity, smoking, diabetes mellitus, alcohol consumption and dyslipidaemia are major risk factors for coronary heart disease and stroke. 1 The recently published HOT study has demonstrated that aggressive tackling of high BP by adjusting target diastolic BP to р85 mm Hg can reduce major cardiovascular events. 2 Consequently, adjustment of BP to normal levels and subsequent control are crucial. Accordingly, the Swiss Society Against High Blood Pressure now suggests a target BP of 135 mm Hg (systolic) and 85 mm Hg (diastolic).
Apart from issues directly related to the drug effects (eg, adverse events, poor tolerability etc), patients' compliance remains one of the major limitations of disease management in hypertension (reviewed in Urquhart 4 ). The European ASPIRE study taking place in nine countries revealed that less than 50% of all treated hypertensive patients are adjusted to BP values in the normal range of diastolic BP (DBP) Ͻ90 mm Hg and systolic BP (SBP) Ͻ140 mm Hg. 5 Therefore, simple treatment and strict BP control schedules are needed to assure the patients' motivation and discipline to participate in disease management.
Compliance
Patient compliance refers to the willingness and ability of an individual to follow health-related advice, eg, to take medication as prescribed, to attend scheduled doctoral appointments and to participate in recommended investigations. Poor compliance is the most common cause of non-response to medication and has been reported to increase morbidity, mortality and cost utilisation. On the other hand there is evidence that patients following , and Burt et al 7 ) . It has also been shown that patients' compliance increases significantly with a once daily treatment regime. 8, 9 Rationale of the SVATCH (Standard vs Automatic Treatment Control of COSAAR ® in Hypertension) Study
To evaluate the influence of home BP measurement on the efficacy of antihypertensive treatment, a population of patients treated with the very same drug would be required. Losartan was chosen since it is used as a first-line antihypertensive drug recommended by the Swiss Society Against High Blood Pressure. 3 It provides good BP lowering and allows simple once daily application. Drug-related adverse effects of losartan are minimal. 10 So it would be unlikely that the effect of the intervention could be jeopardised by an unpredictable adverse event pattern.
In studies with other medications, home measurement of BP has been shown to improve compliance. [11] [12] [13] It could therefore be expected that the efficacy of losartan would be enhanced by providing the patients with a simple method of measuring BP at home.
In this open, randomised, prospective, multicentre study taking place in 244 Swiss practices, 845 patients with mild-to-moderate hypertension on losartan monotherapy were randomised either to a group receiving a home BP measuring device (OMRON) or to a group where this device was not provided. Primary end-point of this study was to compare the responder rates between subjects performing home measurement of BP (group 2) with those without self-measurement (group 1). 'Response' was defined as BP below or equal to 90 mm Hg diastolic, based on physicians measurements after 8 weeks of treatment with losartan. Secondary end-point was the evaluation of the responder rate of patients newly treated for hypertension after 8 weeks whose BP had been normalised to or below 90 mm Hg DBP or had at least been reduced by 10 mm Hg DBP, compared to the baseline at the start of study. A total of 622 subjects completed the study per protocol and were included into efficacy analyses.
Patients and methods
Study design and variables
The SVATCH Study was set up as an open, multicentre, randomised, comparative study, with mildto-moderate hypertensive patients treated with losartan in monotherapy, during an 8-week study period. Investigators were 244 practitioners in general practices in Switzerland. These practitioners received four numbered case record forms (CRFs) each and two Omron ® HEM-605 BP watches (OMRON Healthcare GmbH, Hamburg, Germany). Consecutive patients with newly diagnosed or known hypertension were invited to participate in the study, screened for admission and exclusion criteria (Table 1 ) and when eligible, included into the study. Patients were then randomised either to the group with a BP home measuring device (OMRON, Hamburg) (group 2), or to the other group with BP control in the doctor's practice only (group 1). All patients were treated with 50 mg losartan once daily and instructed to take their medication in the morning. Consequently, they were given 56 tablets of losartan 50 mg for once daily administration for the 8-week study period. The group with self measurement additionally received the material and instructions for operation of the OMRON devices. After the admission visit, patients were examined again at the end of the second and the eighth week of treatment with losartan (see Table 2 for details). Patients could be switched from other antihypertensive drugs ('pretreated', ie, BP lowering drugs had been taken for at least 4 weeks before study start and patients were non-responders to previous medication or medication had to be changed due to side effects) or were considered new cases if they had not taken antihypertensive medication in the 4 weeks prior to admission.
Both admission and treatment evaluations were based on the sphygmomanometric examinations performed at the physician's office in the morning before intake of the daily medication when losartan concentration was at trough. After 5 min of rest, three consecutive measurements within a 1-min interval were performed while the patient was sitting, and the mean value of the three measurements at trough was included into the results.
The self-measurements of BP with the Omron BP watch were carried out at home twice daily (in the morning before losartan intake and 12 h later, in the evening) during the second and the eighth week of the study. The patients were instructed to measure their BP in the wrist area after 5 min of rest, in a sitting position and with the arm elevated to heart level, performing three consecutive measurements. The values recorded by the patients were written into a logbook, but not considered for efficacy analysis since office BP readings were performed by a different person (namely the doctor and not the patient) and based on a different method. Apparently, there is a notable deviation of OMRON wrist BP values and those obtained by conventional sphygmomanometric upper arm measurements. 14 At the end of an 8-week treatment period, the percentage of responders in each group was determined and compared.
Statistical analysis
Results of BP measurement are expressed as responder rates (%). Differences between values are indicated as probability P, whereby P Ͻ 0.05 was considered significant.
Additionally, logistic regression analysis (backward elimination after Hosmer and Lemeshow 15 ) was used to assess the effect of further parameters (eg, gender, pre-treatment, age, body mass index (BMI), concomitant diseases and therapies) on the responder rate.
To compare the two treatment groups at baseline, univariate statistics were used; a non-parametric test (Wilcoxon-Mann-Whitney) for continuous variables and Fisher's exact test (two tailed) as well as GLM for categorical data. Blood pressure values are indicated as means ± standard error. Significance values for changes in BP were determined by Wil- 
Results
A total of 853 hypertensive patients were screened by 244 participating practitioners. While eight patients were excluded from losartan treatment, 845 patients were randomly assigned to one of the two groups; 716 patients fulfilled the inclusion criteria; 83 patients had to be excluded because they violated the study protocol; 36 patients dropped out and of those, 17 subjects discontinued due to adverse events. Only the data of 622 patients were considered for per protocol analysis of efficacy. In contrast, all 845 subjects entering the study were included into safety analysis.
There were no significant or relevant differences between patients initially randomised to group 1 (without) or group 2 (with home measurement device). This also holds true for the 622 patients included into the per protocol efficacy analysis at the end of the 8-week study period. The patient demographics of the two test groups were so similar that statistical analysis was omitted at the start of the study. For the patients included into the efficacy analysis at the end of the 8-week study period, a statistical evaluation of variation between groups was performed as described in the methods section.
Efficacy analysis
General parameters: The mean age of the 622 patients randomised who correctly completed the trial was 57.9 ± 11.8 years; 50.8% of the patients were females. The mean age of the 240 patients who at admission classified as 'pre-treated' with other antihypertensive drugs for at least 4 weeks was somewhat higher than the age of the newly diagnosed hypertensives (group 1/group 2: pre-treated, 61.3 ± 11.1 and 58.8 ± 11.0 years; new cases, 57 ± 12 and 56.3 ± 12 years; NS). In most cases the change of treatment was due to unsatisfactory response to the previous medication (52.7%), adverse events (32%), or both (11.8%). A washout phase between therapy alterations was not performed. Demographic data of the study population are summarised in Table 3 .
In order to assess the patients' adherence to home BP measurement, logbooks of the subjects of group 2 were collected and BP values counted. As is apparent from Table 4 , there are no significant differences between sexes. The males performed slightly more measurements than the females; on average about 75% of the necessary measurements were executed. The BP values of the OMRON wrist measurements were not used for further analysis (see also method section).
The treatment with losartan significantly decreased diastolic and systolic BP in both females and males, as shown in Figure 1 (P Ͻ 0.0001 for t = 2 w; P Ͻ 0.0001 for t = 8 w, vs baseline at t = 0). The mean drop of diastolic and systolic BP was slightly larger in group 2 (on average 1.2 mm Hg DBP at week 2 and 1.4 mm Hg DBP at week 8, and 3.2 mm Hg SBP at week 2 and 2.5 mm Hg SBP at week 8, respectively), while there were no significant changes of heart rate. Considering all the patients pooled, the mean heart rate was 76.5 (s.e. = 0.43) beats per minute (bpm) at admission, 76.0 (s.e. = 0.39) bpm after 2 weeks of treatment and 75.0 (s.e. = 0.38) bpm at the end of the 8 weeks study period.
Primary end-point: evaluation of responders with DBP р90 mm Hg in the different groups
The comparison between the two groups with regard to the responder rates is shown in Table 5 . Total population analysis revealed an improvement in the home measurement cohort by 6.4% (0.05 Ͻ P Ͻ 0.1). This improvement reached statistical significance only in females (P Ͻ 0.01) (increase of 9.1%), whereas in males self-measurement did not seem to have any effect on response. The patients who had already been treated with antihypertensive drugs and did not perform home BP control showed the lowest responder rates (54.8%). However, a 9% increase of response was observed in this subgroup after home BP measurement (0.05 Ͻ P Ͻ 0. 
Determinants of responder rate
The logistic stepwise backward regression, using the responder rate as dependent variable and the study groups, sex, age, BMI, blood pressure at admission, previous treatment in the last 4 weeks ('pre-treated'), concomitant diseases and/or treatments and adverse events during the study as independent variables, only explained 17.4% of the total variance (R 2 after Nagelkerke 1991 16 ). In this model, the sex of the patients had the largest influence, since males responded much worse than females (R = −0.21), followed by pre-treatment, with a lower responder rate (R = −0.17), and by BMI, since overweight individuals also showed a lower responder rate (R = −0.13). All other variables were not relevant at all and eliminated from the model.
Safety analysis
For safety analysis all 845 randomised patients were considered. In total there were only 7.5% adverse event reports during the entire 8-week study period. The most frequent adverse events were nausea/ malaise (1.6% at week 2, 0.5% at week 8) and dizziness (1.6% at week 2, 0.4% at week 8); others had an incidence of less than 1%. In three cases the investigator reduced the losartan dose to 25 mg daily (mainly due to dizziness in two cases and malaise in one case). The two hospitalisations occurring in the course of the study were not causally related to treatment with losartan, for one patient underwent a planned prostatectomy after the study and the other patient was hospitalised with an atypical angina pectoris syndrome, possibly related to gastroesophageal reflux. In 1.4% of the cases an adverse event was reported which was considered 'severe' by the investigator (2 rash, 1 myalgia, 1 lumbosacral pain, 1 edema, 2 dizziness, 2 vertigo, 1 prostate trouble, 1 bronchitis, 1 malaise cases). In one patient, worsening of angina pectoris occurred and a decompensation of a cardiac insufficiency happened in another. Thirty-six patients discontinued prior to week 8 (4.3% drop-outs), of those, 17 drop-outs were related to adverse events. Of the other 19 subjects, two patients discontinued the study because of insufficient efficacy, another two persons did not comply and 15 people did not finish the study for various, unknown reasons. With regard to the two groups, 10 and seven adverse event drop-outs were observed in group 1 (without HBPM) and group 2 (with HBPM), respectively. Six patients of group 1 stopped the trial for other reasons, while more than
Journal of Human Hypertension twice as many, namely 13, subjects of group 2 abandoned the study.
Discussion
Losartan rapidly and significantly reduced diastolic and systolic BP in both treatment groups. Confirming the excellent efficacy of losartan, which has been described in several studies before, 10,17 also
Journal of Human Hypertension Responder rates are in %. HBPM, home blood pressure measurement. P refers to levels of statistical significance between groups. under practice conditions, the SVATCH study revealed that home measurement leads to a slightly bigger decrease of both systolic (by 2.5 mm Hg on average, after 8 week treatment) and diastolic BP (by 1.4 mm Hg on average, after 8 week treatment) and consequently, to an increased response rate in the intervention group. With regard to the primary endpoint target, defined as DBP р90 mm Hg, there was an overall improvement of 6.4%. This result represents a strong trend, even though just missing statistical significance (0.05 Ͻ P Ͻ 0.1). Our findings do not disagree with previously published data, documenting an improvement of BP control by self measurement, especially in patients with bad compliance. [11] [12] [13] However, the SVATCH study did not put emphasis on selecting patients with a poor history of adherence to therapy, but randomly included individuals with good and bad compliance. In contrast to this observation, another trial did not reveal any benefits in BP control when home measurement devices were applied. 18 With regard to primary end-point response, our study uncovered a significant sex-specific difference. The magnitude of this difference is startling and if confirmed, a specific approach to compliance improvement should be tested. The responder rate of women executing home measurement was significantly higher than that of women with office BP measurement alone (P Ͻ 0.01). In contrast, there was no response effect of home measurement in males. The difference between men and women could not be explained by a negligent measurement discipline in the male study group. As a matter of fact, the numbers of BP measurement values carried out were almost identical in females and males. There was even a tendency towards a better measurement discipline in men.
The actual values obtained from home BP measurement were not further analysed, since there was no control on the correctness of the patients' application and since the OMRON device was not equipped with an electronic recording system memorising BP data. Since the study was lacking a compliance measurement tool for drug intake, we do not have any information about individual adherence to medication, and cannot decide whether or not improved BP control may have been linked to disciplined drug application. A specific study on the effects of home BP measurement could be envisaged for evaluating whether or not compliance measurement devices could alter compliance per se.
Pre-treated patients did not respond as well as newly treated subjects. Apparently, most patients with a long history of hypertension undergo changes of therapy either because of inadequacy of the old drug(s), or because of adverse events. In such patients, the regulation of BP to normal levels may be harder than in newly diagnosed patients, or else change of therapeutic class would have been needless. In this context, our findings that response was elevated in the home measurement group by 9.0% may offer a realistic option for better BP control in this population. Even though the total percentage of responder rate increase looks high, it did not prove to be significant, due to the low number of individuals included (n = 240 total pre-treated patients).
In the secondary end-point, the SVATCH study aimed at evaluating the responder rate of the new hypertensive patients (eg, those having not received treatment for at least 1 month prior to start of study). These showed a high responder rate of 79.5% on average (DBP р90 mm Hg or reduction of DBP by у10 mm Hg from baseline), exceeding established data for treatment of hypertension. 10, 19 Home BP measurement did not have a significant effect on BP control in this population (81.4% vs 77.7%), and therefore cannot be recommended for new hypertensive patients.
The safety profile of losartan is similar to what has been described in controlled trials before. 10, 20 The incidence of adverse events was low; there were no reports of severe events. The 8-week drop-out rate of 4.3% was small as well, thus confirming the good tolerance of losartan. Home BP measurement did not have a positive effect on the drop-out rate, since more than twice as many patients of the intervention group discontinued the trial for reasons other than adverse events, compared to the group without the home measurement device. This finding contradicts the results of an earlier study where self-measurement of BP significantly decreased the drop-out rate. 18 Since in the present study drop-out rates were about 10% lower than in the previous study of 1988 18 and since drug treatment was different too, a fair comparison of results may not be possible.
Although the SVATCH study has failed to demonstrate a significant, clinically important additional benefit of home BP measurement for a hypertensive population in general practices, it showed that a home BP measuring device can be useful for small reductions of BP in the range of 1.5-3 mm Hg, especially in the female subgroup and in pre-treated patients. Since home BP measurement can increase the patients awareness for the disease (reviewed in Schaub et al 11 ) and potentially also the patients' participation in hypertension management, even the smallest improvements of BP may act as reinforcement. However, a recommendation for widespread use of home BP measurement tools based on our results cannot be made when costs are taken into consideration. From a cost-effectiveness viewpoint, the additional small increase in BP control does not seem to be economical. A final analysis to assess the economical aspects of our study still needs to be done.
